Innate Pharma S.A. (IPHYF)
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Innate Pharma S.A. (IPHYF) ist im Healthcare-Sektor taetig, zuletzt notiert bei $ mit einer Marktkapitalisierung von 0. Bewertet mit 44/100 (vorsichtig) bei Wachstumspotenzial, finanzieller Gesundheit und Momentum.
Zuletzt analysiert: 15. März 2026Innate Pharma S.A. (IPHYF) Gesundheitswesen & Pipeline-Uebersicht
Innate Pharma S.A., a French biotechnology firm, specializes in developing innovative immunotherapies for cancer, focusing on NK cell biology and antibody engineering. With a diverse pipeline of clinical-stage assets and strategic partnerships, the company aims to address unmet needs in cancer treatment on a global scale.
Investmentthese
Innate Pharma presents a compelling, albeit high-risk, investment opportunity within the biotechnology sector. The company's focus on innovative immunotherapies, particularly those targeting NK cells, positions it at the forefront of cancer treatment advancements. Key value drivers include the successful progression of Lacutamab and Monalizumab through clinical trials, with potential FDA approval representing significant upside. Strategic collaborations with major pharmaceutical companies like AstraZeneca and Sanofi provide financial support and validation of Innate Pharma's technology. However, the company's negative gross margin of -243.7% and high debt-to-equity ratio of 525.45 indicate financial challenges. Successful clinical trial outcomes and partnership expansions are crucial for long-term value creation.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market capitalization of $0.19 billion reflects the company's current valuation in the biotechnology market.
- Gross margin of -243.7% indicates significant costs associated with research and development activities.
- Return on Equity (ROE) of -271.4% suggests challenges in generating profits from shareholders' equity.
- Debt-to-Equity ratio of 525.45 indicates a high level of financial leverage.
- Free Cash Flow (FCF) of $-0.00B reflects ongoing investment in research and development.
Wettbewerber & Vergleichsunternehmen
Staerken
- Innovative immunotherapy pipeline.
- Focus on NK cell biology.
- Strategic collaborations with major pharmaceutical companies.
- Experienced management team.
Schwaechen
- Negative gross margin.
- High debt-to-equity ratio.
- Reliance on clinical trial success.
- Limited commercialization experience.
Katalysatoren
- Upcoming: Phase II clinical trial results for Lacutamab (IPH4102) in cutaneous T-cell and peripheral T-cell lymphoma.
- Upcoming: Phase III clinical trial results for Monalizumab in advanced solid tumors.
- Ongoing: Expansion of strategic collaborations with pharmaceutical companies.
- Ongoing: Progress in preclinical development of new NK cell engagers.
- Ongoing: Potential for FDA approval of key drug candidates.
Risiken
- Potential: Clinical trial failures for key drug candidates.
- Potential: Regulatory setbacks or delays.
- Ongoing: Competition from other immunotherapy companies.
- Ongoing: High research and development costs.
- Ongoing: Financial challenges due to negative gross margin and high debt.
Wachstumschancen
- Growth opportunity 1: Successful clinical trials and regulatory approvals for Lacutamab (IPH4102) represent a significant growth opportunity. The drug is currently in Phase II trials for cutaneous T-cell and peripheral T-cell lymphoma, as well as refractory sézary syndrome. Positive trial results and subsequent FDA approval could lead to substantial revenue generation, addressing a market with unmet medical needs. The timeline for potential approval is dependent on trial outcomes, but could be within the next 2-3 years.
- Growth opportunity 2: Advancing Monalizumab through Phase III clinical trials for advanced solid tumors, including colorectal, lung, and head and neck cancers, offers another key growth avenue. Positive results and subsequent commercialization could significantly expand Innate Pharma's market reach and revenue streams. The potential market for these indications is substantial, with a timeline for potential approval within the next 2-4 years.
- Growth opportunity 3: Expanding strategic collaborations with pharmaceutical companies like AstraZeneca, Novo Nordisk A/S, and Sanofi provides financial resources and expertise to accelerate drug development. These partnerships can lead to milestone payments, royalties, and co-development opportunities, enhancing Innate Pharma's long-term growth prospects. The ongoing collaborations are expected to continue driving innovation and value creation.
- Growth opportunity 4: Developing and commercializing new NK cell engagers, such as IPH6401 and IPH6101, targeting BCMA and CD123, respectively, represents a promising growth area. These innovative therapies have the potential to address unmet needs in hematological malignancies and other cancers. The timeline for potential commercialization is dependent on preclinical and clinical trial progress, but could be within the next 3-5 years.
- Growth opportunity 5: Progressing preclinical programs like IPH43, IPH45, and IPH67 into clinical development offers long-term growth potential. These early-stage assets target various tumor antigens and immunosuppressive pathways, providing opportunities to expand Innate Pharma's pipeline and address a broader range of cancers. The timeline for potential clinical trials is dependent on preclinical data, but could be within the next 1-2 years.
Chancen
- Successful clinical trial outcomes.
- Regulatory approvals for key drug candidates.
- Expansion of strategic collaborations.
- Development of new NK cell-based therapies.
Risiken
- Clinical trial failures.
- Regulatory setbacks.
- Competition from other immunotherapy companies.
- Patent expirations.
Wettbewerbsvorteile
- Proprietary NK cell biology expertise.
- Strong intellectual property portfolio covering key drug candidates.
- Strategic collaborations with leading pharmaceutical companies.
- Advanced antibody engineering capabilities.
Ueber IPHYF
Innate Pharma S.A., founded in 1999 and based in Marseille, France, is a biotechnology company dedicated to discovering, developing, and commercializing innovative immunotherapies for cancer. The company's focus is on harnessing the innate immune system to fight cancer, particularly through Natural Killer (NK) cell biology and antibody engineering. Innate Pharma's pipeline includes several clinical-stage assets, such as Lacutamab (IPH4102), an anti-KIR3DL2 antibody in Phase II trials for cutaneous T-cell and peripheral T-cell lymphoma, as well as refractory sézary syndrome. Monalizumab, an immune checkpoint inhibitor, is in Phase III trials for advanced solid tumors including colorectal, lung, and head and neck cancers. Other assets include IPH5201, IPH5301, IPH6401, IPH6101, and IPH62, targeting various immunosuppressive pathways and tumor antigens. The company also has preclinical programs like IPH43, IPH45, and IPH67. Innate Pharma collaborates with pharmaceutical companies like AstraZeneca, Novo Nordisk A/S, Sanofi, and MedImmune Limited to advance its research and development efforts. The company operates internationally, seeking to address unmet medical needs in cancer treatment worldwide.
Was das Unternehmen tut
- Develop immunotherapies for cancer patients.
- Focus on harnessing the innate immune system to fight cancer.
- Develop Natural Killer (NK) cell-based therapies.
- Engineer antibodies to target specific cancer cells.
- Conduct clinical trials to evaluate the safety and efficacy of their therapies.
- Collaborate with pharmaceutical companies to advance research and development.
- Target immunosuppressive pathways to promote antitumor immunity.
Geschaeftsmodell
- Develop and out-license novel immunotherapies to larger pharmaceutical companies.
- Generate revenue through milestone payments and royalties from partnered programs.
- Retain rights to certain programs for independent development and commercialization.
- Collaborate with research institutions to identify and validate new drug targets.
Branchenkontext
Innate Pharma operates within the competitive biotechnology industry, which is characterized by rapid innovation, high research and development costs, and stringent regulatory requirements. The immunotherapy market, in which Innate Pharma specializes, is experiencing substantial growth, driven by the increasing prevalence of cancer and advancements in immune-based therapies. Key trends include the development of novel checkpoint inhibitors, cell therapies, and antibody-drug conjugates. Innate Pharma competes with established pharmaceutical companies and other biotechnology firms, striving to differentiate itself through its focus on NK cell biology and strategic collaborations.
Wichtige Kunden
- Cancer patients in need of innovative treatment options.
- Pharmaceutical companies seeking to expand their oncology portfolios.
- Research institutions and academic centers involved in cancer research.
- Healthcare providers who prescribe and administer cancer therapies.
Finanzdaten
Chart & Info
Innate Pharma S.A. (IPHYF) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer IPHYF verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer IPHYF.
Kursziele
Wall-Street-Kurszielanalyse fuer IPHYF.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von IPHYF auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Wettbewerber & Vergleichsunternehmen
IPHYF OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that Innate Pharma S.A. may not meet the minimum financial or reporting standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries a higher degree of risk compared to those listed on major exchanges like NYSE or NASDAQ.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure.
- Higher price volatility.
- Lower trading volume.
- Potential for fraud or manipulation.
- Less regulatory oversight.
- Verify the company's management team and their track record.
- Review available financial statements and assess the company's financial health.
- Research the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal issues.
- Confirm the company's contact information and physical address.
- Established partnerships with reputable pharmaceutical companies (AstraZeneca, Sanofi).
- Presence of multiple clinical-stage assets in the pipeline.
- Focus on innovative immunotherapy research.
- Incorporated in 1999, indicating a long operating history.
Haeufige Fragen zu IPHYF
What are the key factors to evaluate for IPHYF?
Innate Pharma S.A. (IPHYF) currently holds an AI score of 44/100, indicating low score. Key strength: Innovative immunotherapy pipeline.. Primary risk to monitor: Potential: Clinical trial failures for key drug candidates.. This is not financial advice.
How frequently does IPHYF data refresh on this page?
IPHYF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven IPHYF's recent stock price performance?
Recent price movement in Innate Pharma S.A. (IPHYF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative immunotherapy pipeline.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider IPHYF overvalued or undervalued right now?
Determining whether Innate Pharma S.A. (IPHYF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying IPHYF?
Before investing in Innate Pharma S.A. (IPHYF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding IPHYF to a portfolio?
Potential reasons to consider Innate Pharma S.A. (IPHYF) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Innovative immunotherapy pipeline.. Additionally: Focus on NK cell biology.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of IPHYF?
Yes, most major brokerages offer fractional shares of Innate Pharma S.A. (IPHYF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track IPHYF's earnings and financial reports?
Innate Pharma S.A. (IPHYF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for IPHYF earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Information is based on available company data and may be subject to change.
- OTC market data may be limited and less reliable than major exchange data.